The colorectal cancer market in North America is expected to grow from US$ 8,559.27 million in 2022 to US$ 11,198.11 million by 2028; it is estimated to grow at a CAGR of 3.4% from 2022 to 2028.
Colorectal cancer is one of the most commonly found lethal cancers in individuals with the combined influence of genetic and environmental factors. A significant population in North America is diagnosed with colorectal cancer. According to the Centers for Disease Control and Prevention (CDC) and the American Cancer Society, an estimated 1.93 million adults in the US were diagnosed with colon and rectum cancer, and 53,200 deaths were caused by colorectal cancer in 2020. These statistics showcase increased demand for advanced cancer diagnostics and therapeutics in the region. Thus, the rising prevalence of colorectal cancer and the rising number of patients diagnosed with the disease are driving the growth of the North America colorectal cancer market.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the North America colorectal cancer market at a substantial CAGR during the forecast period.
๐ ๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐
๐๐จ๐ฉ๐ฒ@ https://www.businessmarketinsights.com/sample/TIPRE00009241
North America Colorectal Cancer Strategic Insights
Strategic insights for the North America Colorectal Cancer provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.
๐๐
๐ฎ๐ฅ๐ฅ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐ข๐ง๐ค @ https://www.businessmarketinsights.com/reports/north-america-colorectal-cancer-market
North America Colorectal Cancer Market
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in North America, and it remains a significant public health concern due to its high incidence, mortality rates, and the economic burden it places on healthcare systems. The North American colorectal cancer market encompasses a wide array of diagnostic, therapeutic, and monitoring products and services aimed at the prevention, early detection, and treatment of this disease. In this article, we explore the market landscape, key drivers, challenges, and emerging trends shaping the North American colorectal cancer market.
Overview of Colorectal Cancer
Colorectal cancer refers to cancer that begins in the colon or rectum, both parts of the large intestine. CRC is the third most commonly diagnosed cancer in both men and women in the United States, after breast and prostate cancers. It is also one of the leading causes of cancer-related deaths in the region. The disease develops when abnormal cells in the colon or rectum grow uncontrollably, leading to the formation of tumors.
Segments Covered
By Modality
Diagnosis Type
Therapy Type
Imaging Type
By End User
Risk factors for colorectal cancer include age (most cases occur in individuals aged 50 or older), family history of the disease, lifestyle factors such as diet, smoking, physical inactivity, and obesity, as well as conditions such as inflammatory bowel disease (IBD) and certain genetic syndromes. Early detection through regular screenings, such as colonoscopies, can help identify precancerous growths or cancers in their early stages, improving treatment outcomes.
๐๐ก๐ ๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐จ๐ฆ๐ฉ๐๐ง๐ข๐๐ฌ
Abbott
Amgen Inc.
Bruker Corporation
Clinical Genomics Technologies Pty Ltd.
Epigenomics AG
F. Hoffmann-La Roche AG
Quest Diagnostics
VolitionRx Limited
Market Segmentation
The North American colorectal cancer market can be segmented based on various factors, such as diagnostic methods, treatment options, and geographical regions.
Diagnostic Market: The diagnostic segment includes procedures and tests used to detect colorectal cancer. This includes:
Colonoscopy: The most widely used procedure to examine the colon and rectum.
Stool-based tests: Non-invasive tests such as fecal occult blood test (FOBT), fecal immunochemical test (FIT), and multitarget stool DNA test (e.g., Cologuard).
Imaging techniques: CT colonography and MRI can also be used for screening and diagnosis.
Liquid biopsy: An emerging area that uses blood samples to detect genetic mutations associated with colorectal cancer.
Therapeutic Market: The therapeutic segment is dominated by:
Chemotherapy: Standard treatment for advanced CRC, including agents like fluorouracil (5-FU), oxaliplatin, and irinotecan.
Targeted therapies: Drugs that specifically target cancer cells, such as EGFR inhibitors (e.g., cetuximab) and VEGF inhibitors (e.g., bevacizumab).
Immunotherapy: Immune checkpoint inhibitors like pembrolizumab and nivolumab have been gaining traction in the treatment of certain types of colorectal cancer, particularly those with high microsatellite instability (MSI-H).
Surgical procedures: Surgical resection remains a common treatment for early-stage colorectal cancer, often followed by chemotherapy or radiotherapy.
Treatment by Stage: The stage of colorectal cancer at diagnosis significantly affects treatment options. Early-stage cancers may require surgery alone, while advanced cancers often involve a combination of chemotherapy, targeted therapy, and immunotherapy.
Geography: North America is largely dominated by the U.S. market, but Canada also represents a significant portion of the regional market. Both countries have relatively high healthcare standards and access to advanced treatment options, which contribute to the overall market size.
Challenges in the Market
Despite the significant advances in the treatment and detection of colorectal cancer, there are still several challenges that hinder market growth:
High Treatment Costs: The cost of colorectal cancer treatment, especially biologic and targeted therapies, can be prohibitively expensive. This poses a significant barrier to access for some patients, particularly those without insurance or with inadequate coverage.
Screening Participation Rates: Despite recommendations for routine screening, many individuals do not undergo regular screenings due to lack of awareness, fear, or barriers to access such as cost and time constraints. Screening rates are lower among underserved populations, which can lead to late-stage diagnoses and poor outcomes.
Side Effects and Treatment Resistance: Some colorectal cancer treatments, particularly chemotherapy, can cause severe side effects that reduce patients' quality of life. Additionally, patients may develop resistance to certain treatments, limiting their effectiveness over time.
Late Diagnosis: Colorectal cancer is often diagnosed at advanced stages when treatment options are limited. Late-stage diagnosis continues to be a major challenge in improving survival rates.
๐๐๐จ๐ฎ๐ญ ๐๐ฌ:
Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications
You can see this-
North America Tortilla Market- https://www.openpr.com/news/3927532/north-america-tortilla-market-segments-opportunities
3D and 4D Technology Market- https://www.openpr.com/news/3921417/3d-and-4d-technology-market-segments-opportunities-regional
Last Mile Delivery Market- https://www.openpr.com/news/3921138/last-mile-delivery-market-global-analysis-size-share